These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31032691)

  • 1. First-time prescription of enzalutamide in a patient treated with fluindione and digoxin: serial drug interactions.
    Strobbe G; Pannier D; Villain A; Feutry F; Marliot G
    Acta Oncol; 2019 Aug; 58(8):1167-1169. PubMed ID: 31032691
    [No Abstract]   [Full Text] [Related]  

  • 2. Falsely Elevated Digoxin Levels in Patients on Enzalutamide.
    Kalra D; Tesfazghi M
    Circ Heart Fail; 2020 Jul; 13(7):e007008. PubMed ID: 32527146
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzalutamide and analytical interferences in digoxin assays.
    Deguigne M; Brunet M; Abbara C; Turcant A; Le Roux G; Lelièvre B
    Clin Toxicol (Phila); 2018 Nov; 56(11):1150-1154. PubMed ID: 29741399
    [No Abstract]   [Full Text] [Related]  

  • 4. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
    Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentre F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
    Cerebrovasc Dis; 2001; 12(3):245-52. PubMed ID: 11641591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling INR data to predict maintenance fluindione dosage.
    Comets E; Mentré F; Pousset F; Diquet B; Montalescot G; Ankri A; Mallet A; Lechat P
    Ther Drug Monit; 1998 Dec; 20(6):631-9. PubMed ID: 9853979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can colchicine potentiate the anticoagulant effect of fluindione?
    Gras-Champel V; Ohlmann P; Polard E; Wiesel ML; Imbs JL; Andréjak M
    Eur J Clin Pharmacol; 2005 Aug; 61(7):555-6. PubMed ID: 16007421
    [No Abstract]   [Full Text] [Related]  

  • 7. [Esomeprazole-induced resistance to fluindione: An unrecognized interaction].
    Ayme-Dietrich E; Aubertin-Kirch G; Andrès E; Monassier L
    Therapie; 2016 Jun; 71(3):337-41. PubMed ID: 27235659
    [No Abstract]   [Full Text] [Related]  

  • 8. [Analysis of a circulating anticoagulant in the course of treatment with an antivitamin K. Importance in a febrile patient].
    Henrionnet A; Béchade D; Algayres JP; Daly JP
    Presse Med; 2000 Mar; 29(10):542. PubMed ID: 10761521
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.
    Comets E; Diquet B; Legrain S; Huisse MG; Godon A; Bruhat C; Chauveheid MP; Delpierre S; Duval X; Berrut G; Verstuyft C; Aumont MC; Mentré F
    Clin Pharmacol Ther; 2012 May; 91(5):777-86. PubMed ID: 22472992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
    Benoist GE; van Oort IM; Smeenk S; Javad A; Somford DM; Burger DM; Mehra N; van Erp NP
    Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide.
    Shatzel JJ; Daughety MM; Olson SR; Beer TM; DeLoughery TG
    J Oncol Pract; 2017 Nov; 13(11):720-727. PubMed ID: 29125921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of digoxin levels falsely affected by enzalutamide.
    Lammoza N; Hormiz M; Chiang C; Stead C; Ayhan M; Hume SC
    Med J Aust; 2024 May; 220(9):455-456. PubMed ID: 38655578
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 14. Immuno-allergic interstitial nephritis related to fluindione: first biopsy proven cases.
    Grimaldi D; Daugas E; Mougenot B; Rossert J; Ronco P
    Nephrol Dial Transplant; 2006 Jan; 21(1):237. PubMed ID: 16221711
    [No Abstract]   [Full Text] [Related]  

  • 15. [Warfarin switch from fluindione in elderly patients].
    Peyro Saint Paul L; Martin J; Moslemi I; Le Hello C; Le Querrec A
    Presse Med; 2014 Feb; 43(2):221-3. PubMed ID: 24184283
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma digoxin concentrations in patients with atrial fibrillation and indications for the association with other antiarrhythmic agents.
    Cargnelli G; Domeneghetti F; Ferrari M; Malacini P; Roberti G
    Int J Clin Pharmacol Biopharm; 1977 Aug; 15(8):384-8. PubMed ID: 892956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
    Del Re M; Fogli S; Derosa L; Massari F; De Souza P; Crucitta S; Bracarda S; Santini D; Danesi R
    Cancer Treat Rev; 2017 Apr; 55():71-82. PubMed ID: 28340451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.
    Nhean S; Bravo J; Sheehan NL; Walmsley S; Tilley D; Tseng AL
    AIDS; 2018 Nov; 32(17):2640-2642. PubMed ID: 30379691
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 20. Garlic interaction with fluindione: a case report.
    Pathak A; Léger P; Bagheri H; Senard JM; Boccalon H; Montastruc JL
    Therapie; 2003; 58(4):380-1. PubMed ID: 14679681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.